Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years

References

• Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328:1323–1332.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–340.
   PubMed Web of Science ®Google Scholar
• Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. N Engl J Med. 1989;321(21):1449–1459.
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164–170.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80(6):1430–1436.
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319–324.
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in cancer chemotherapy patients. Am J Clin Oncol. 2012;35(3):267–274.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12(11):2471–2508.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993;85(6):488–493.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34(12):1857–1864.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Update recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957–1960.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony-stimulating factors: the American society of clinical oncology survey. The health services research committee of the American society of clinical oncology. J Clin Oncol. 1996;14(9):2511–2520.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Weeks JC, Somerfield MR, et al. Use of hematopoietic colony-stimulating factors: comparison of the 1994–1997 American society of clinical oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol. 1999;17(11):3676–3681.
   PubMed Web of Science ®Google Scholar
• Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol. 2000;18(8):1764–1770.
   PubMed Web of Science ®Google Scholar
• Du XL, Lairson DR, Begley CE, et al. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol. 2005;23(34):8620–8628.
   PubMed Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18(20):3558–3585.
   PubMed Web of Science ®Google Scholar
• Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903–909.
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10(3):715–724.
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23(9):2283–2295.
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11(1):404.
   PubMed Web of Science ®Google Scholar
• Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131–3140.
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13(1):11.
   PubMed Web of Science ®Google Scholar
• Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm. 2003;9(2):15–S21.
   PubMedGoogle Scholar
• Chrischilles EA, Rubenstein LM, Voelker MD, et al. Granulocyte colony-stimulating factor use during first course chemotherapy for non-Hodgkin’s lymphoma: national SEER-Medicare study. Blood. 2003;102(11):499A.
   Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402–407.
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim versus filgrastim prophylaxis: a retrospective cohort study. Clin Ther. 2009;31(5):1069–1081.
   PubMed Web of Science ®Google Scholar
• SEC Filing. Amgen’s website. [cited 2016 Oct 20]. Available from: http://investors.amgen.com/financial-information/annual reports.
   Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–4531.
   PubMed Web of Science ®Google Scholar
• Weycker D, Barron R, Edelsberg J, et al. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat. 2012;133(1):301–310.
   PubMed Web of Science ®Google Scholar
• Hershman D, Wilde ET, Wright JD, et al. Uptake and economic impact of first-cycle colony-stimulating factor and use during adjuvant treatment of breast cancer. J Clin Oncol. 2012;30(8):806–812.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, McCune JS, Blough DK, et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Pharmacotherapy. 2010;16(9):678–686.
   Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6(2):109–118.
   PubMedGoogle Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13(4):337–348.
   PubMed Web of Science ®Google Scholar
• Kozma CM, Dickson M, Chia V, et al. Trends in neutropenia-related inpatient events. J Oncol Pract. 2012;8(3):149–150.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid growth factors in cancer treatment. Version 2. 2005. Available from: www.nccn.org
   Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle of use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–1184.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1(1):23–35.
   PubMedGoogle Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): myeloid growth factors, version 2.2019, 03/27/19. Fort Washington (PA): National Comprehensive Cancer Network, Inc; 2019.
   Google Scholar
• Sung L, Nathan P, Alibhai S, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400–411.
   PubMed Web of Science ®Google Scholar
• Bunn PA, Jr., Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrohage colony-stimulation factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of Southwest Oncology Group. J Clin Oncol. 1995;13(7):1632–1641.
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Greil R, Hausmaninger H, et al. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multicenter trial by the Austrian Working Group for medical tumor therapy. Ann Hematol. 1997;75:135–140.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484.
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–1924.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266.
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008;19(3):454–460.
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991–2997.
   PubMed Web of Science ®Google Scholar
• Numnum TM, Kimball KJ, Rocconi RP, et al. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer. 2007;17(5):1019–1024.
   PubMed Web of Science ®Google Scholar
• Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11(2):172–179.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12(2):217–225.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Eng J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25(2):401–411.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009;31(5):1092–1104.
   PubMed Web of Science ®Google Scholar
• Danova M, Chiroli S, Rosti G, et al. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori. 2009;95(2):219–226.
   PubMed Web of Science ®Google Scholar
• Liu Z, Doan QV, Malin J, et al. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193–205.
   PubMedGoogle Scholar
• Weycker D, Li X, Figueredo J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer. 2015;24:2309–2316.
   PubMed Web of Science ®Google Scholar
• Billingsley CC, Jacobson SN, Crafton SM, et al. Evaluation of the hematologic safety of same day versus standard administration (24- to 72- hour delay) of pegfilgrastim in gynecology oncology patients undergoing cytotoxic chemotherapy. Int J Gynecol Cancer. 2015;25(7):1331–1336.
   PubMed Web of Science ®Google Scholar
• Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6(3):133–140.
   PubMedGoogle Scholar
• Whitworth JM, Matthews KS, Shipman KA, et al. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol. 2009;112(3):601–604.
   PubMed Web of Science ®Google Scholar
• Cheng C, Gallagher EM, Yeh J-Y, et al. Rates of febrile neutropenia with pegfilgrastim on same versus next day of CHOP with or without rituximab. Anticancer Drugs. 2014;25(8):964–969.
   PubMed Web of Science ®Google Scholar
• Weycker D, Bensink M, Lonshteyn A, et al. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33:2107–2113.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hanau A, Lonshteyn A, et al. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. Curr Med Res Opin. 2018;34(9):1705–1711.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Allcott K, Garcia J, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy induced neutropenia: a systematic review. Support Care Cancer. 2017;25(8):2619–2629.
   PubMed Web of Science ®Google Scholar
• Aarts MJ, Peters FP, Mandigers CM, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. 2013;31(34):4290–4296.
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Barron R, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Support Care Cancer. 2016;24(6):2481–2490.
   PubMed Web of Science ®Google Scholar
• Weycker D, Bensink M, Wu H, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Curr Med Res Opin. 2017;33:2115–2120.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hanau A, Lonshteyn A, et al. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using medicare claims. Curr Med Res Opin. 2019;35(4):725–730.
   PubMed Web of Science ®Google Scholar
• Drugs.com. Neulasta sales data. [cited 2016 Dec 25]. Available from: https://www.drugs.com/stats/neulasta.
   Google Scholar
• Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst. 2011;103(12):910–913.
   PubMedGoogle Scholar
• Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060–2065.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–1724.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hillner BE. A way forward on the medically appropriate use of white cell growth factors. J Clin Oncol. 2012;30(14):1584–1587.
   PubMed Web of Science ®Google Scholar
• Waters GE, Corrigan P, Gatesman M, et al. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract. 2013;9(4):203–206.
   PubMedGoogle Scholar
• Weycker D, Bensink M, Lonshteyn A, et al. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010–2016: a longitudinal assessment. Curr Med Res Opin. 2019;35(6):1073–1080.
   PubMed Web of Science ®Google Scholar
• Agiro A, Ma Q, Acheson AK, et al. Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. J Clin Oncol. 2016;34(32):3872–3879.
   PubMed Web of Science ®Google Scholar
• Weycker D, Lonshteyn A, Doroff R, et al. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: a retrospective observational study. BMC Cancer. 2019;19(1):792.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Yau L, Nakov R, et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol. 2018;29(9):1903–1910.
   PubMed Web of Science ®Google Scholar
• Whyte S, Cooper KL, Stevenson MD, et al. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health. 2011;14(4):465–474.
   PubMed Web of Science ®Google Scholar
• Hill G, Barron R, Fust K, et al. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. J Med Econ. 2014;17(1):32–42.
   PubMedGoogle Scholar
• Fust K, Li X, Maschio M, et al. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecol Oncol. 2014;133(3):446–453.
   PubMed Web of Science ®Google Scholar
• Lee EK, Wong WWL, Trudeau ME, et al. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015;150(1):169–180.
   PubMed Web of Science ®Google Scholar
• Skedgel C, Rayson D, Younis T. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in BC? Support Care Cancer. 2016;24(1):387–394.
   PubMed Web of Science ®Google Scholar
• Fust K, Li X, Maschio M, et al. Cost-effectiveness analysis of prophylaxis treatment strategic to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma. Pharmacoeconomics. 2017;35(4):425–438.
   PubMed Web of Science ®Google Scholar
• Lathia N, Isogai PK, Angelis CD, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against neutropenia in lymphoma patients. J Natl Cancer Inst. 2013;105(15):1078–1085.
   PubMedGoogle Scholar
• Chan KK, Siu E, Krahn MD, et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012;30(10):1064–1071.
   PubMed Web of Science ®Google Scholar
• Marion S, Tzivelekis S, Darden C, et al. Same-day” administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016;24(9):3889–3896.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN trends. Results: August 2013, granulocyte-colony stimulating factor. National Comprehensive Cancer Network, Inc.; 2013.
   Google Scholar
• Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Legg JC, et al. Assessing patients’ risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med. 2015;4(8):1153–1160.
   PubMed Web of Science ®Google Scholar